Clinical Trials Browser

Phase 1/2 × INDUSTRY × lumiliximab × Clear all

NCT00103558 2015-10-02

Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

Phase 1/2 Completed

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell